Halozyme slides on an ear­ly fu­til­i­ty fail­ure for its lead can­cer ther­a­py

Halozyme shares slipped 8% on Thurs­day af­ter the biotech re­port­ed that one of its com­bo stud­ies us­ing PEGPH20 couldn’t clear an ear­ly test for fu­til­i­ty.

In­ves­ti­ga­tors were us­ing a com­bi­na­tion of PEGPH20 plus Folfiri­nox against Folfiri­nox alone on pre­vi­ous­ly un­treat­ed metasta­t­ic pan­cre­at­ic can­cer, a tough chal­lenge for any drug. Now the San Diego-based biotech has halt­ed en­roll­ment as it analy­ses the da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER